2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.19 Efficacy and Outcomes of Immunotherapy-Based Treatments in EGFR-Mutant Non-Small Cell Lung Cancer

Pdf Summary

This study investigates the effectiveness of immunotherapy (IO) and IO combined with chemotherapy (IOC/T) in treating advanced epidermal growth factor receptor-mutant non-small cell lung cancer (EGFR-mutant NSCLC) following the failure of first- to second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Conducted at Taipei Veterans General Hospital from 2014 to 2022, the study retrospectively analyzed 107 patients who progressed after EGFR-TKI therapy and underwent either IO alone or IOC/T as subsequent treatments.<br /><br />The study divided participants into two groups: 33 patients received IO alone and 74 received IOC/T. Results indicated an objective response rate (ORR) of 20% for both groups, but the disease control rate (DCR) was higher in the IOC/T group (69%) compared to the IO group (53%). Treatment involving platinum-based chemotherapy showed significantly higher ORR compared to non-platinum-based options, especially when combined with pemetrexed.<br /><br />Data suggested that patients in the IOC/T group experienced a marginally longer overall survival (OS) and time to treatment failure (TTF) than those in the IO group, though the differences were not statistically significant (OS: 20 vs. 16 months; TTF: 4 vs. 2 months). Moreover, patients who received more than four lines of treatment before starting IO-based therapies exhibited poorer outcomes in terms of OS and TTF.<br /><br />The study concludes that incorporating IO-based treatments early in the therapeutic regime for EGFR-mutant NSCLC can potentially enhance survival rates. Delaying IO-based treatment until after multiple lines of previous treatments appear to adversely affect overall outcomes, emphasizing the importance of earlier integration of immunotherapy in treatment strategies.

Asset Subtitle

Yung-Hung Luo

Meta Tag

Speaker Yung-Hung Luo

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

immunotherapy

chemotherapy

EGFR-mutant NSCLC

epidermal growth factor receptor

non-small cell lung cancer

EGFR-TKIs

Taipei Veterans General Hospital

disease control rate

overall survival

treatment strategies